CTOs on the Move

Aimmune

www.aimmune.com

 
Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.aimmune.com
  • 8000 Marina Boulevard Suite 200
    Brisbane, CA USA 94005
  • Phone: 650.614.5220

Executives

Name Title Contact Details
Narinder Singh
Executive Vice President of Technical Operations Profile

Funding

Aimmune raised $80M on 11/04/2016
Aimmune raised $200M on 02/05/2020

Similar Companies

Synsorb Biotech

Synsorb Biotech Inc. is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spine Team Texas

Spine Team Texas is a Southlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Incellico Inc

Incellico Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entasis

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.

Elevian

Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.